Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 7 results.
User Information
Export Records
  1. 1.   Antibody-drug conjugates for cancer
  2. Chau, Cindy H.; Steeg,Pat; Figg, William D.
  3. Lancet (London, England). 2019, Aug 31; 394(10200): 793-804.
  1. 2.   HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
  2. Zielinski, R.; Lyakhov, I.; Hassan, M.; Kuban, M.; Shafer-Weaver, K.; Gandjbakhche, A.; Capala, J.
  3. Clinical Cancer Research. 2011, Aug; 17(15): 5071-5081.
  1. 3.   Pharmacogenomics and cancer stem cells: a changing landscape?
  2. Crea, F.; Duhagon, M. A.; Farrar, W. L.; Danesi, R.
  3. Trends in Pharmacological Sciences. 2011, Aug; 32(8): 487-494.
  1. 4.   A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
  2. Kelly, R. J.; Draper, D.; Chen, C. C.; Robey, R. W.; Figg, W. D.; Piekarz, R. L.; Chen, X. H.; Gardner, E. R.; Balis, F. M.; Venkatesan, A. M.; Steinberg, S. M.; Fojo, T.; Bates, S. E.
  3. Clinical Cancer Research. 2011, Feb; 17(3): 569-580.
  1. 5.   Monitoring Drug-Induced gamma H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
  2. Wang, L. H.; Pfister, T. D.; Parchment, R. E.; Kummar, S.; Rubinstein, L.; Evrard, Y. A.; Gutierrez, M. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.; Kinders, R. J.
  3. Clinical Cancer Research. 2010, Feb; 16(3): 1073-1084.
  1. 6.   Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-anticancer drug screen: Correlation with sensitivity to microtubule active agents
  2. Nicoletti, M. I.; Valoti, G.; Giannakakou, P.; Zhan, Z. R.; Kim, J. H.; Lucchini, V.; Landoni, F.; Mayo, J. G.; Giavazzi, R.; Fojo, T.
  3. Clinical Cancer Research. 2001 7(9): 2912-2922.
  1. 7.   Resistance to Paclitaxel Mediated By P-Glycoprotein Can Be Modulated By Changes in the Schedule of Administration
  2. Zhan, A. R.; Scala, S.; Monks, A.; Hose, C.; Bates, S.; Fojo, T.
  3. Cancer Chemotherapy and Pharmacology. 1997 40(3): 245-250.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel